DTIL

SEC filing DTIL Reports $1.2B Revenue, $0.15 EPS, +45% YoY; Announces PBGENE-HBV cccDNA Elimination Data at EASL 2026; Investor Webcast Today

6d ago

SEC filing DTIL Stockholders Approve 3.8M Share Increase in 2019 Incentive Award Plan, Amend Certificate for Officer Exculpation

6d ago

News Here are the major earnings before the open Tuesday

27d ago

News Precision BioSciences GAAP EPS of -$0.75 misses by $0.09, revenue of $10.84M beats by $6.79M

28d ago

News Precision BioSciences GAAP EPS of $1.05 beats by $1.59, revenue of $34M beats by $24.93M

82d ago

Insider trade Sale by Jefferson J. Smith

104d ago

Insider trade Sale by Michael Amoroso

104d ago

Insider trade Sale by John Alexander Kelly

104d ago

Insider trade Sale by Dario Scimeca

104d ago

SEC filing DTIL Receives FDA Clearance for PBGENE-DMD, Enabling Phase 1/2 Clinical Trial for Duchenne Muscular Dystrophy

111d ago

Scanner Unusual volume (z=4.9)

160d ago

Scanner Unusual volume (z=4.5)

162d ago

Scanner Unusual volume (z=4.5)

163d ago

Scanner Unusual volume (z=4.5)

164d ago